Home > Rheumatology > ACR 2020 > Spotlight on Rheumatoid Arthritis > Rheumatoid arthritis: new EULAR treatment guidelines

Rheumatoid arthritis: new EULAR treatment guidelines

Presented By
Prof. Daniel Aletaha, Medical University Vienna, Austria
Conference
ACR 2020
Trial
IDEA, NORD-STAR
Several new developments have led to changes in the EULAR recommendations to treat rheumatoid arthritis. They include the use of JAK inhibitors, short-term corticosteroid administration, and treatment tapering. The new EULAR guidelines on the management of rheumatoid arthritis (RA) were presented by Prof. Daniel Aletaha (Medical University Vienna, Austria) [1,2]. His presentation covered the following topics: treat-to-target and remission, precision medicine, expanding therapeutic opportunities, glucocorticoids, and possible treatment reduction decisions [1]. The treat-to-target approach has been widely implemented among rheumatologists for about 10 years. Remission criteria are not new, but recently, there has been some discussion on the role of Patient Global Assessment (PGA) within the Boolean criteria. There is ongoing research about the use of increasing the cut-off point for the PGA to improve the consistency of the Boolean criteria with the S...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on